An FDA complete response letter, often abbreviated CRL, tells an applicant that the agency has completed its review cycle and cannot approve the marketing application in its present form. It identifies deficiencies that must be addressed for the application to move forward.
A CRL is not approval. It is also not necessarily a permanent rejection of the product.
The letter ends a review cycle
FDA issues a complete response after reviewing a new drug application or biologics license application when outstanding problems prevent approval. The action replaces the older practice of issuing “approvable” or “not approvable” letters.
The letter can recommend actions that might place the application in condition for approval. Depending on the deficiencies, those actions can range from analyses or manufacturing corrections to new clinical studies.
The phrase “complete response” describes the agency's communication, not completion of the product's development.
Deficiencies can arise from different parts of the application
A CRL may address:
- insufficient evidence of effectiveness;
- safety concerns or inadequate risk management;
- trial conduct or data-integrity issues;
- statistical analysis;
- manufacturing process or facility inspection findings;
- product quality, stability, or specifications;
- device or human-factors issues in a combination product;
- proposed labeling;
- need for additional information.
Public sponsor summaries often disclose only selected points. Unless the letter is released, outsiders may not know every deficiency or the exact language FDA used.
A facility problem can block an otherwise persuasive clinical package
Approval requires more than a positive trial. FDA must be able to find that the marketed product can be manufactured consistently and that facilities comply with applicable requirements.
A CRL citing inspection observations does not necessarily invalidate clinical efficacy. Conversely, fixing a facility does not resolve a deficient efficacy package. The part of the application affected should be stated precisely.
Resubmission starts another review process
The applicant can amend or resubmit after addressing the letter, request a meeting, seek formal dispute resolution, or withdraw the application. FDA classifies certain resubmissions, with different review goals based on the scope of the response.
A resubmission accepted for review is not approval. The new action date is another review target, and FDA can approve or issue another complete response.
Some programs receive multiple CRLs before approval; others are discontinued.
Check FDA's public CRL database
FDA expanded public access to CRLs in 2025. It first released a batch associated with applications that were later approved, then announced that it would promptly release future CRLs and published letters for pending or withdrawn applications. The openFDA database now includes letters associated with both approved and unapproved applications.
Publication does not mean every application detail is public. Letters can be redacted, and the database may not contain every historical letter. Search the public database and the product's approval package before relying only on a sponsor press release or securities filing.
Reporting should still distinguish “the company said the CRL cited…” from “FDA's published letter states….” When a letter is available, identify its date and application number and check for later resubmissions or approval.
A CRL is different from a clinical hold
A clinical hold applies to an investigational study under an IND and can delay or suspend clinical work. A complete response applies to a marketing application at the end of a review cycle.
The two can arise in the same development program but address different regulatory stages. A refuse-to-file action is different again: it concerns whether a submitted application is sufficiently complete to permit substantive review.
Market status can be indication-specific
A product already approved for one use can receive a CRL for a supplemental application seeking a new indication, population, formulation, or manufacturing change. Headlines saying “FDA rejected the drug” can therefore be misleading.
Always identify:
- original or supplemental application;
- exact proposed indication;
- dosage form or manufacturing change;
- whether any other indications remain approved;
- date and outcome of later resubmissions.
How to follow the record
Build a timeline from:
- application submission;
- filing acceptance and review designation;
- advisory committee materials, if any;
- target action date;
- sponsor disclosure of the CRL;
- FDA public statements, if available;
- meetings and planned remedial work;
- resubmission acceptance;
- later approval or another action.
Read the final approved label rather than assuming the resubmitted indication matches the original request.
Accurate wording
FDA issued a complete response letter stating that the application could not be approved in its current form. According to the sponsor, the letter identified [disclosed deficiency]. The company [has/has not] announced a resubmission as of [date].
Avoid “FDA banned the drug” unless a separate legal action actually did so. Also avoid “minor delay” when the scope of required work is unknown.
Bottom line
A complete response letter is a formal non-approval action for the current review cycle. It marks real deficiencies, but the long-term outcome depends on what those deficiencies are and whether the applicant can resolve them. Precise reporting names the application, source of public details, and later status.
Sources
- U.S. Food and Drug Administration. Complete Response Letter Final Rule.
- Electronic Code of Federal Regulations. 21 CFR 314.110, Complete response letter to the applicant.
- Electronic Code of Federal Regulations. 21 CFR 601.3, Complete response letter to the applicant.
- U.S. Food and Drug Administration. Drugs@FDA.
- U.S. Food and Drug Administration. FDA Announces Real-Time Release of Complete Response Letters. September 4, 2025.
- U.S. Food and Drug Administration. openFDA Complete Response Letters database.
Continue reading
Editorial responsibility and corrections
Published by Serum Research. Sources checked October 1, 2026. This is educational material; no independent scientific, clinical, statistical, analytical, or regulatory review is claimed. Read how we review evidence or send a correction.
For Research Use Only. Not for Human Consumption. This page does not provide instructions for medical use or establish the identity, quality, safety, or equivalence of a catalog material.